Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-FU, and methyl-CCNU.

Abstract

Twenty-four patients with advanced metastatic colorectal cancer with measurable sites of disease were treated with a combination of 5-FU, methyl-CCNU, ICRF-159, and triazinate. Only two had objective regression of disease. Two patients died of complications from drug-induced myelosuppression. Toxic effects were moderate in the remaining patients. Attempts to escalate doses were limited by myelosuppression. The regimen used has no advantage over 5-FU alone. It is unlikely that triazinate and ICRF-159 will add substantially to the efficacy of chemotherapy for colorectal cancer.

• Authors: S E Vogl, R Qazi, M Berenzweig
• Journal: Cancer treatment reports (Cancer Treat Rep) 1980 Oct-Nov Vol. 64 Issue 10-11 Pg. 1143-5 ISSN: 0361-5960 [Print] United States
• PMID: 7459902 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Nitrosourea Compounds
• Piperazines
• Triazines
• Semustine
• Razoxane
• triazinate
• Fluorouracil

Topics

• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Colonic Neoplasms (drug therapy)
• Drug Therapy, Combination
• Female
• Fluorouracil (therapeutic use)
• Humans
• Male
• Middle Aged
• Nitrosourea Compounds (therapeutic use)
• Piperazines (therapeutic use)
• Razoxane (therapeutic use)
• Rectal Neoplasms (drug therapy)
• Semustine (adverse effects, therapeutic use)
• Triazines